Highlights in Hyepria’s results:
-
Net Revenue Growth : Hypera Pharma recorded a 5.0% growth in Net Revenue in the third quarter of 2023, reaching R$2,138.5 million. This performance was driven by the recent increase in sales in pharmacies, e-commerce platforms and growth in the Institutional Market.
-
Challenges in Specific Categories: The company faced challenges in categories such as Flu, Respiratory, Pain and Fever, due to the reduction in the number of flu cases in Brazil in the third quarter. However, Hypera Pharma managed to maintain its market share in these categories.
-
Growth in the Institutional Market: The Institutional Market contributed significantly to the company's Net Revenue , with growth of 18.3% compared to the same period of the previous year. This growth was the result of initiatives implemented to boost the product portfolio, recent launches and expansion of sales teams.
The company also released its EBITDA results from Continuing Operations, which reached R$774.1 million, a margin of 36.2%, and an Operating Cash Flow of R$724.4 million . Furthermore, Hypera Pharma had already declared Interest on Equity of R$194.8 million and received recognition for its sustainable practices. The company maintains an optimistic view and estimates Net Revenue growth of 8% in 2023.